The authors of the CONVERT trial speculated that with prophylactic G-CSF, patients received the same dose intensity of chemotherapy in subsequent cycles instead of dose reduction after severe neutropenia, possibly resulting in a higher incidence of other myelosuppression. This evidence concerns the gene CSF3 and neutropenia.